Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease

详细信息    查看全文

• 作者：Uma Mahadevan¹ ; ^{uma.mahadevan@ucsf.edu} ; Ryan A. McConnell¹ ; Christina D. Chambers²
• 关键词：Inflammatory Bowel Disease ; Pregnancy ; Anti&minus ; Tumor Necrosis Factor
• 刊名：Gastroenterology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：152
• 期：2
• 页码：451-462.e2
• 全文大小：434 K
• 卷排序：152

文摘

The management of the pregnant patient with inflammatory bowel disease is complicated by multiple providers, misinformation, and a disease entity that, particularly when active, can adversely affect pregnancy outcomes. This article seeks to frame the debate on medication safety in pregnancy and lactation using the US Food and Drug Administration's new Pregnancy and Lactation Labeling Rule and the most up-to-date safety information to discuss the risks and benefits of using each class of inflammatory bowel disease medication.